



GLAND PHARMA LIMITED

October 30, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra
(East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Appointment of Chief Executive Officer for Gland Pharma International Pte. Ltd (Wholly-owned subsidiary of Gland Pharma Limited)

We would like to inform you that Mr. Ajay Sahni has been appointed as the Chief Executive Officer of Gland Pharma International Pte. Ltd., ('Gland Singapore'), the Wholly-owned subsidiary of the Company, effective 2nd November, 2026.

Mr. Ajay Sahni will be responsible for Cenexi business, a wholly owned step-down subsidiary of Gland Pharma Limited, effective 2nd November, 2026. He shall be reporting to the CEO of Gland Pharma Limited.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in **Annexure-A** enclosed herewith.

This is for your information and records.

Yours truly,

For Gland Pharma Limited

Pallerlamudi
Sampath Kumar

Digitally signed by Pallerlamudi
Sampath Kumar
DN: cn=Pallerlamudi Sampath
Kumar, c=IN, o=Personal,
email=Sampath@glandpharma.com
Date: 2026.10.30 16:28:12 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer

Encl: Annexure A

Regd. Office:

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India
Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office:

Plot No. 11 & 84, TSIC Phase: IV
Pashamylaram (V), Patancheru (M), Sangareddy District
Hyderabad 502307, Telangana, India
Tel: +91-8455-699999

**Annexure A**

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Details of Mr. Ajay Sahni

SI. No	Particulars	Remarks
1	Reason for change & Date of Change	Mr. Ajay Sahni, has been appointed as the Chief Executive Officer of Gland Singapore and will be responsible for Cenexi business, effective 2 nd November, 2026.
2	Brief profile	<p>Mr. Ajay Sahni has over 36 years of experience in FMCG & Pharmaceutical industries, in the areas of financial management, business development and general management.</p> <p>He has a vast experience performing all kinds of roles including Finance Director, Project Manager- Business Development, Director (Financial Control, Planning and Analysis), Regional Finance Director for South and South-East Asia, President, and Managing Director in various companies viz., Sanofi SA, Sanofi-Synthelabo Inc., Sanofi-Synthelabo Pte. Ltd, Ferring Pharmaceuticals, Wockhardt France SAS and multiple subsidiaries including Laboratoires Negma SAS, Wockhardt Bio AG. and Pinewood Healthcare Ltd. He has worked in various countries like France, Belgium, Ireland, Switzerland, Singapore, and USA.</p> <p>Mr. Ajay in his previous leadership roles, was the Managing Director for Pinewood Healthcare Ltd, Ireland; Managing Director for Wockhardt Bio AG, Switzerland; President of Wockhardt France SAS and its subsidiaries.</p> <p>Mr. Ajay holds a Bachelor's degree in Business Administration from European University of Brussels, Belgium.</p>
3	Disclosure of relationships between director	Not Applicable
4	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable